$36.59 0.47 (+1.30%)
11/20/2009 4:00 PM

Eli Lilly & Co. (LLY)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.

Results 1 - 20 of 144 1 2 3 4 5 6 7 8 Next »

Recs

0
Member Avatar TzingerToo (< 20) Submitted: 11/2/2009 6:51:47 PM : Outperform Start Price: $33.43 LLY Score: +3.97

Solid dividend. News from expiring patents has expired.

Recs

0
Member Avatar Somnambulo (96.60) Submitted: 10/29/2009 2:38:37 PM : Underperform Start Price: $33.45 LLY Score: -6.76

I would recommend googling Simpsonwood document, which shows that the CDC and vaccine manufacturers were aware of mounting evidence that vaccines are linked to autism. Add to this a new scientific report that shows a link between neurological damage and vaccines for adults, which will set the stage for litigation by veterans who suffer from Gulf War Syndrome.

Eli Lilly owns the patent to Thimerasol, a deadly neurotoxin that is still used in flu shots and vaccines exported to third world countries. Adjuvant such as aluminium and squaline may help Eli cut costs, but the proof of detrimental side effects is mounting. I see large class action law suits piling up soon in the next couple of years.

Recs

0
Member Avatar budshex (< 20) Submitted: 10/23/2009 12:21:26 AM : Outperform Start Price: $33.65 LLY Score: +8.94

The balance sheet hurts my eyes to look at. The numbers are so large I have a hard time wrapping my head around the dynamics of a company of that size. No less a pharmaceutical company. What I do understand is that the dividend is unfazed. It hasn't seen any runs on pricing. In my mind it's not so much a hot stock as a great 5 year CD. Start 34.15 Stop 28.60

Recs

0
Member Avatar darksabre (27.72) Submitted: 10/21/2009 3:15:53 PM : Outperform Start Price: $33.30 LLY Score: +9.67

Solid Company

Recs

0
Member Avatar richardrogers4 (64.75) Submitted: 10/19/2009 3:45:37 PM : Outperform Start Price: $34.80 LLY Score: +5.64

technical breakout

Recs

0
Member Avatar SmallPimpin (98.44) Submitted: 9/24/2009 7:36:12 PM : Outperform Start Price: $31.93 LLY Score: +10.16

Mmm...pharmaceuticals...

Recs

0
Member Avatar jemsa (82.75) Submitted: 9/16/2009 9:19:11 PM : Outperform Start Price: $32.34 LLY Score: +10.53

Portefeuille 12. Hoping Eli Lilly will benefit if I am correct in my assumption that medical stocks are next up for big gains.

Recs

0
Member Avatar tomfoolme (92.00) Submitted: 9/6/2009 2:27:34 PM : Outperform Start Price: $32.74 LLY Score: +5.02

div

Recs

0
Member Avatar Momentum21 (68.35) Submitted: 8/13/2009 11:38:05 PM : Outperform Start Price: $32.32 LLY Score: +4.89

Long term pharma with some dividends...good entry I believe

Recs

0
Member Avatar gameguru (< 20) Submitted: 7/13/2009 9:23:14 AM : Outperform Start Price: $31.36 LLY Score: -8.08

As of July 10, 2009, part of the Morningstar Wide Moat Focus index, which tracks the 20 wide-moat firms wide the lowest price-to-fair value ratio. Firms are selected from 174 companies defined as "wide-moat" by Morningstar.

Fair value estimate is listed as $54.
http://news.morningstar.com/articlenet/article.aspx?id=298017

I sometimes wonder how it is that a pharmaceutical stock classifiies as a wide-moat. Yes, they have patent protection, but you know there are many competitors developing new drugs in the same class and the moat will last only as long as the patents (or the tricks that they can use to extend the life of those patents). Maybe "temporary-moat" would be a better term for firms that rely on patent protection for their competitive advantage.

Recs

0
Member Avatar dchabino1 (75.60) Submitted: 6/16/2009 3:32:07 PM : Outperform Start Price: $32.06 LLY Score: -6.59

This stock was chosen as part of a group of stocks based upon criteria which focused heavily on dividend yield, cash flow, and balance sheet information.

Recs

0
Member Avatar foolishjules (80.95) Submitted: 6/15/2009 5:35:08 PM : Outperform Start Price: $32.21 LLY Score: -5.00

MY BROKER RECOMMENDED AND HAVE HELD FOR 5 YEARS

Recs

0
Member Avatar captainBEN (< 20) Submitted: 5/20/2009 3:29:44 PM : Outperform Start Price: $33.84 LLY Score: -13.57

Great dividend!!!!!!!

Recs

0
Member Avatar ipfmanager (98.28) Submitted: 5/5/2009 5:26:49 PM : Outperform Start Price: $33.77 LLY Score: -12.24

byetta that diabetes drug should light things up....in about a year.

Recs

0
Member Avatar slider12 (42.48) Submitted: 4/30/2009 10:46:01 PM : Outperform Start Price: $31.55 LLY Score: -10.49

What's better for a depression than antidepressants?

Recs

0
Member Avatar mikiocii (47.70) Submitted: 4/30/2009 5:51:00 PM : Outperform Start Price: $31.55 LLY Score: -10.49

Dividends, Health Care and drugs for aging population. Plenty of money to buy other companies and develop new drugs.

Recs

0
Member Avatar AllanYangMusic (< 20) Submitted: 4/21/2009 6:35:50 PM : Outperform Start Price: $31.73 LLY Score: -15.83

Eli Lily is one of the best and most consistently well managed companies. It understand the ebb and tides.

Recs

0
Member Avatar BuyerKen (< 20) Submitted: 4/4/2009 4:58:55 AM : Outperform Start Price: $31.39 LLY Score: -16.05

Top stock pick in a highly successful mutual fund in spite of performance since Oct 08. High yield dividend too. Price target $40 by June 09.

Recs

0
Member Avatar bartleyrc (85.27) Submitted: 3/29/2009 4:39:26 PM : Outperform Start Price: $30.70 LLY Score: -19.49

Over 11% annualized revenue growth over the last 5 years and a solid pipeline position LLY to outperform the S&P.

Recs

0
Member Avatar whtcllrchaingang (< 20) Submitted: 3/24/2009 1:38:31 PM : Outperform Start Price: $32.32 LLY Score: -21.80

High dividend yield puts the floor under it. Has top mkt share of anti depressants and many are looking to consume that product in the next yr.

Featured Broker Partners